We are live on ! Find out more

BridgeBio Pharma

BBIO

Market cap $13.8B

70.82 USD

+1.45

2.09%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

70.82

0.00

0%

1 day

2.09%

5 days

4.95%

1 month

6.32%

3 months

-17.22%

6 months

1.59%

Year to date

-9.48%

1 year

9.8%

5 years

40.24%

10 years

157.06%

About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Employees: 839

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.1%

Neutral 59.1%

Negative 6.8%

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its third quarter 2026 financial results and business update after the market closes on Thursday, October 29, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Zacks Investment Research

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on October 14, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 32 new employees in restricted stock units for an aggregate of 57,853 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

BridgeBio Pharma maintains a "Strong Buy" rating, driven by robust revenue growth and multiple late-stage pipeline catalysts. The company delivered Q2 2026 net revenues of $243.7M, up from the prior year's $110.6M, outperforming despite competition. Three NDA submissions—BBP-418, oral infigratinib, and encaleret—are under Priority Review, with PDUFA dates spanning late 2026 to mid-2027.

BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

Zacks Investment Research

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) will be shared at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place in Boston, Massachusetts on October 9-12, 2026.

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one oral presentation, three rapid-fire oral presentations, and six poster presentations on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2026, taking place in Phoenix, Arizona on October 9-12, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus 40% in the placebo arm (p=0.0248); HS troponin I, a blood marker of heart muscle injury, declined more with BBP-418 than placebo (LS mean difference -17.8 ng/L; 95% CI: -35.1 to -0.5; p=0.0443)

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

See News Rankings

Price charts implemented using Lightweight Charts™